Previous Close | 173.94 |
Open | 174.85 |
Bid | 176.70 x 1000 |
Ask | 176.61 x 1200 |
Day's Range | 174.07 - 177.15 |
52 Week Range | 155.72 - 186.69 |
Volume | |
Avg. Volume | 7,883,030 |
Market Cap | 465.918B |
Beta (5Y Monthly) | 0.72 |
PE Ratio (TTM) | 26.45 |
EPS (TTM) | 6.69 |
Earnings Date | Apr 18, 2022 - Apr 22, 2022 |
Forward Dividend & Yield | 4.52 (2.56%) |
Ex-Dividend Date | May 23, 2022 |
1y Target Est | 191.42 |
Immix Biopharma Inc (NASDAQ: IMMX) announced positive interim data from an animal study in Soft Tissue Sarcoma (STS). STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for trabectedin in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study. Trabectedin is sold as Yondelis by Janssen, a Johnson & Johnson (NYSE: JNJ) com
We discuss areas that could outperform in the current market environment.
Companies could be returning trillions to shareholders. Here’s how to accept it.